Cargando…

Cerebrospinal Fluid Levels of Amyloid Beta 1–43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer’s Disease: A 2-Year Follow-Up Study

Introduction: Biomarkers that will reliably predict the onset of Alzheimer’s disease (AD) are urgently needed. Although cerebrospinal fluid (CSF) amyloid beta 1–42 (Aβ42), total tau, and phosphorylated tau can be used to complement the clinical diagnosis of AD, amnestic mild cognitive impairment (aM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lauridsen, Camilla, Sando, Sigrid B., Shabnam, Adiba, Møller, Ina, Berge, Guro, Grøntvedt, Gøril R., Bakken, Inger J., Salvesen, Øyvind, Bråthen, Geir, White, Linda R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772322/ https://www.ncbi.nlm.nih.gov/pubmed/26973507 http://dx.doi.org/10.3389/fnagi.2016.00030

Ejemplares similares

Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42
por: Lauridsen, Camilla, et al.
Publicado: (2017)

The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2020)

Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study
por: Berge, Guro, et al.
Publicado: (2016)

Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2022)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
por: Twohig, Daniel, et al.
Publicado: (2018)

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease
por: Patra, Kalicharan, et al.
Publicado: (2018)

Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease
por: Giannisis, Andreas, et al.
Publicado: (2022)

In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
por: Hessen, Erik, et al.
Publicado: (2019)

Incidence of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2020)

The Prevalence and Subtypes of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2019)

Time to Diagnosis in Young Onset Alzheimer’s Disease: A Population-Based Study from Central Norway
por: Kvello-Alme, Marte, et al.
Publicado: (2021)

Comparison of Amyloid Positivity Rate and Accumulation Pattern between Amnestic and Non-Amnestic Type Mild Cognitive Impairment
por: Lee, Sun Hyung, et al.
Publicado: (2020)

Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
por: Berge, Guro, et al.
Publicado: (2014)

Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects
por: Coutinho, Artur M N, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnestic Mild Cognitive Impairment
por: Park, Jung Eun, et al.
Publicado: (2019)

Cerebrospinal Fluid Homer-3 Autoantibodies in a Patient with Amnestic Mild Cognitive Impairment
por: Hansen, Niels, et al.
Publicado: (2023)

Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients
por: Tomadesso, Clémence, et al.
Publicado: (2018)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment
por: Kim, Hyung-Ji, et al.
Publicado: (2022)

The short-term effect of a modified comprehensive geriatric assessment and regularly case conferencing on neuropsychiatric symptoms in nursing homes: a cluster randomized trial
por: Stensvik, Geir-Tore, et al.
Publicado: (2022)

Usefulness of a national parent experience survey in quality improvement: views of paediatric department employees
por: Iversen, Hilde Hestad, et al.
Publicado: (2010)

Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer’s disease patients
por: Kirsebom, Bjørn Eivind, et al.
Publicado: (2022)

Detecting At-Risk Alzheimer’s Disease Cases
por: Fladby, Tormod, et al.
Publicado: (2017)

Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy
por: Putcha, Deepti, et al.
Publicado: (2019)

The Effect of Clinical Characteristics and Subtypes on Amyloid Positivity in Patients with Amnestic Mild Cognitive Impairment
por: Kim, Jeong Yeon, et al.
Publicado: (2019)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2017)

Amnestic MCI Patients’ Perspectives toward Disclosure of Amyloid PET Results in a Research Context
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2017)

Cerebrospinal fluid GAP-43 in early multiple sclerosis
por: Rot, U, et al.
Publicado: (2018)

The Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI
por: Csukly, Gábor, et al.
Publicado: (2016)

Differences in Functional Brain Connectivity Alterations Associated with Cerebral Amyloid Deposition in Amnestic Mild Cognitive Impairment
por: Yi, Dahyun, et al.
Publicado: (2015)

Divergent brain regional atrophy and associated fiber disruption in amnestic and non-amnestic MCI
por: Du, Chao, et al.
Publicado: (2023)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

Carisoprodol-induced amnestic state
por: Gupta, Arun, et al.
Publicado: (2008)

Opioid-Associated Amnestic Syndrome
por: Ciurylo, William, et al.
Publicado: (2021)

Opioid-Associated Amnestic Syndrome
por: Walker, Macey L, et al.
Publicado: (2021)

Qualitative Comparison of Semantic Memory Impairment in Patients with Amnestic Mild Cognitive Impairment Based on β-Amyloid Status
por: Kim, Ji Eun, et al.
Publicado: (2019)

Subjective Sleep Quality in Amnestic Mild Cognitive Impairment Elderly and Its Possible Relationship With Plasma Amyloid-β
por: Liu, Yajing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bp6bnbbi87eeugr6tmsfcflnmk